AIDS Journal

•  
• Overview
•  
• Identity
•  
• Ver todos
•  

Overview

publication venue for

• Chronotropic incompetence in HIV infection.  921-923. 2024
• Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades AIDS. 2022.  249-256. 2022
• Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns.  1301-1303. 2021
• Hepatitis delta in patients hospitalized in Spain (1997-2018).  2311-2318. 2021
• Trends in hospitalizations and deaths in HIV-Infected patients in Spain over two decades 2021
• Hospital admissions in individuals with HTLV-1 infection in Spain.  1019-1027. 2020
• High-grade anal intraepithelial neoplasia is associated with HIV-1 RNA rectal shedding in virologically suppressed MSM..  1017-1024. 2018
• Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.  337-346. 2018
• Switching from a ritonavir-boosted protease inhibitor to a dolutegravir based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.  2503-2514. 2017
• Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors.  37-44. 2016
• Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors..  37-44. 2015
• X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. .  1603-1609. 2014
• Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. .  81-85. 2013
• Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.  2315-2326. 2012
• Differences in the causes of death of HIV-positive subjects in a cohort study by data sources and coding algorithms.  1829-1834. 2012
• Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy.  1-9. 2012
• The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.  1691-1705. 2012
• Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients..  761-766. 2011
• Decline of CD4¿ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals..  1041-1049. 2011
• Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.  1-9. 2010
• Etravirine RAMs in HIV Patients Failing Efavirenz or Nevirapine in the Spanish Antiretroviral Resistance Database.  469-471. 2010
• Risk factors foe sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors.  255-264. 2010
• Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.  1697-1707. 2010
• The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.  123-137. 2010
• Risk Factors foe sexual and erectil dysfunction in HIV-infected men: the role of protease inhibitors.  1-10. 2009
• Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults..  377-384. 2008
• Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV..  1-9. 2008
• Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected patients..  1369-1371. 2008
• Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected-patients.  1369-1371. 2008
• The effect of antiretroviral treatment of different durations in primary HIV infection..  2441-2450. 2008
• Changes in the incidence of tuberculosis in a cohortof HIV-seroconverters before and after the introduction of HAART.  2521-2527. 2007
• Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.  1283-1291. 2007
• Effective therapy has altered the spectrum of causespecific mortality following HIV seroconversion.  741-749. 2006
• Impact of hepatitis C infection on long-term mortality of infection drug users from 1990 to 2002 differences before and after HAART.  111-116. 2006
• Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on..  289-291. 2006
• Techniques for measuring regional body fat: computed tomography may be suitable for evaluation of facial lipoatrophy.  2237-2238. 2006
• AIDS Research in Brazil. .  1-2. 2005
• Geography of medical publications. An overview of HIV/AIDS research in 2003. .  219-220. 2005
• Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. .  2001-2007. 2005
• Unexpected improvement of sexual dysfunction during atazanavir therapy. .  1440-1441. 2005
• CASCADE Collaboration. Short term risk of AIDS by current CD4, viral load and age in naïve individuals and those treated in the monotherapy era..  51-58. 2004
• CASCADE Collaboration. Systemic non-Hodgkin lymphoma in persons with known dates of HIV seroconversion: incidence and predictors..  673-681. 2004
• Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates.  1697-1705. 2004
• Monitoring HIV/AIDS in migrants communities in Europe. .  1867-1873. 2004
• Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.  51-58. 2004
• Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors.  673-681. 2004
• Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, Hatzakis A, Porter K; CASCADE Collaboration. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates..  1697-1705. 2004
• Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.  353-359. 2003
• Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: ifferences by transmission category.  353-359. 2003
• HIV health experiences among migrant Africans ¿ How are we doing?.  2261-2263. 2003
• Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.  594-600. 2003
• Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drug users with known date of HIV seroconversion.  1201-1208. 2003
• Avascular necrosis of the bone in HIV-infected patients: Incidence and associated factors.  471-473. 2002
• Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997..  257-266. 2001

Identity

International Standard Serial Number (ISSN)

• 0269-9370